Quarterly ResultMay 20, 2026, 05:12 PM
Vivos Therapeutics Q1 Net Loss Doubles to $(7.75)M; Revenue Up 70%
AI Summary
Vivos Therapeutics reported a significant increase in net loss to $(7.75) million for Q1 2026, up from $(3.86) million in Q1 2025. Despite the widened loss, total revenue surged by 70.4% to $5.14 million, primarily driven by a 207.6% increase in service revenue, reflecting the company's strategic pivot to a medical-provider focused sales model. This new strategy includes the June 2025 acquisition of The Sleep Center of Nevada and the formation of AIM Detroit LLC in July 2025.
Key Highlights
- Net loss for Q1 2026 doubled to $(7.75) million from $(3.86) million in Q1 2025.
- Total revenue increased 70.4% to $5.14 million in Q1 2026, up from $3.02 million YoY.
- Service revenue surged 207.6% to $3.70 million, reflecting the new medical-provider focused model.
- Product revenue decreased 20.6% to $1.44 million in Q1 2026.
- Operating loss widened to $(6.62) million from $(3.92) million in the prior year period.
- Acquired The Sleep Center of Nevada (SCN) in June 2025 for $6.0 million cash and $1.3 million in stock.
- Formed AIM Detroit LLC in July 2025, holding an 80% ownership interest.
- Net cash used in operating activities increased to $(6.01) million from $(3.80) million YoY.
Price Impact
More from VVOS